mmOligo seeks to improve reliability and speed the development of lifesaving and life-enhancing oligonucleotide-based therapeutics.

mmOligo applies advanced MS-based data analysis for nonstandard and hybrid nucleotide sequences. Direct sequencing via mass spectrometry has become essential for development and for QA/QC of manufacturing of highly modified and highly complex oligonucleotide-based therapeutics.

Our scientists and software developers are delivering semi-automated direct sequencing solutions for the analysis of oligonucleotides by mass spectrometry.

Key Advantages of mmOligo

  • Best-in-class sequencing of oligonucleotides.
  • Expanded capabilities for sequencing hybrid and conjugated oligonucleotides.
  • Interoperable data standard.

The Science Behind mmOligo

Spacer Fidelity Assessments of Guide RNA by Top-Down Mass Spectrometry. Luis A. Macias, Sara P. Garcia, Kayla M. Back, Yue Wu, G. Hall Johnson, Sekar Kathiresan, Andrew M. Bellinger, Ellen Rohde, Michael A. Freitas, and James A. Madsen* ACS Cent. Sci. 2023, XXXX, Publication Date:July 11, 2023

Accelerating Gene Therapy and Editing with Advanced MS-Based Data Analysis for Nonstandard and Hybrid Nucleotide Sequences (Research supported by the National Institute Of General Medical Sciences of the National Institutes of Health under Award Number R44GM152984. The content is solely the responsibility of MassMatrix and does not necessarily represent the official views of the National Institutes of Health.)

Download the mmOligo Product Summary PDF